Drug Makers Intensify Blame Game While Seeking to Avoid Accountability
For Immediate Release
Contact: Jon Conradi
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today issued a statement after fresh evidence that PhRMA and BIO, the principal trade groups representing Big Pharma, have ramped-up their blame game tactics targeting others in the health care system to avoid accountability for their egregious pricing practices.
“Big Pharma is ramping up its blame game attacks in a desperate attempt to distract policymakers from their egregious pricing practices and lead role in the crisis of rising prescription drug prices,” said CSRxP executive director Lauren Aronson. “More than ever, the American people overwhelmingly agree Washington must hold Big Pharma accountable with market-based solutions to increase competition and boost transparency.”
One of the policies brand name drug makers are pushing with renewed vigor, as part of their blame game campaign, is the U.S. Department of Health and Human Services’ (HHS) Rebate Rule.
“Big Pharma’s unvarnished enthusiasm for the proposed Rebate Rule should be enough cause for the administration and lawmakers in Congress to take a step back,” Aronson noted. “Policymakers in Washington should take pause when the leading culprit for the crisis of prescription drug prices in America shows such ardor for a controversial policy.”
“We, of course, know why Big Pharma is so eager to see the Rebate Rule enacted,” Aronson continued. “The rule hands drug makers a more than $100 billion bailout and greater unilateral control over prices at the expense of seniors and taxpayers. At the same time, the nonpartisan Congressional Budget Office (CBO) has confirmed the rule won’t result in lower list prices.”
A recent CSRxP survey, conducted by Morning Consult, found a clear majority of the American people blame Big Pharma’s practices for the crisis of rising prescription drug prices.
The survey also found Americans overwhelmingly want policymakers in Washington to focus on market-based solutions to hold Big Pharma accountable, rather than measures targeting drug rebates.
The poll also demonstrated Americans have serious concerns with and oppose the proposed Rebate Rule.